The same ADC is tested together with PI3K inhibitor alpelisib in metastatic, pretreated HER-2 negative BC in the phase 1 ASSET trial (NCT05143229), and other ADC T-DXd is checked for its safety when administered with nivolumab (an anti-PD1 mAb) in phase 1 NCT03523572 study including patients with BC. The gene discussed is ERBB2; the disease is breast cancer.